Thanks for your response ClosetInvestor Here ar

Thanks for your response ClosetInvestor

Here are three quick comments, with the understanding that I have very little experience in this realm:

1. I honestly don't remember NP definitively stating that leronlimab would be licensed. I am assuming you are saying that CytoDyn will provide a license to one or more distribution companies to sell leronlimab. A bit off topic but we know Leronlimab is a proprietary mAb that is very difficult to produce and can only be made by two companies (Samsung and AGC) -- and only at the request of CytoDyn.

2. Cytodyn's US HIV deal with Vyera was 50/50, not including the Vyera's payment to CytoDyn of COGS +10% and associated royalty payments. Vyera was to provide the entire marketing and sales effort for domestic HIV indications. Even with a licensed distribution partner receiving a percentage of COVID sales, I cannot envision anything like a 50/50 split. I'm not in that business, but that makes no sense to me.

3. Notwithstanding, in what I could only characterize as an absolute (and improbable) worst case scenario of a 50/50 split with a distribution partner, you could halve the P/E multiple projections in my previous post and still find yourself at a very attractive stock price number using a very conservative P/E of 20.

From my original post:

 P/E 05 = 56.25
 P/E 10 = 112.50
 P/E 15 = 168.75
 P/E 20 = 225.00 -- Half of $225 = $112.50 just for US 2021
 P/E 25 = 281.25
 P/E 30 = 337.50
 P/E 35 = 393.75
 P/E 40 = 450.00